<![CDATA[BackgroundTumor cells have the ability to change the phenotype of inflammatory cells in the tumor environment into protumoral factors. One ofthe mediators produced such as interleukin 17 (IL-17) also plays a role in increasing tumor proliferation and invasion. Similar to IL-17,Ki67 has generally been used as a marker to assess the extent of breast carcinoma proliferation. This is the first study to determinethe relationship of IL-17 expression with Ki67 proliferation index of breast carcinoma patients.MethodsThis is a case series study using 38 paraffin block samples of breast carcinoma patients. The clinicopathological characteristicsdocumented are age, histopathological subtype and grade, TILs (tumor infiltrating lymphocytes) and molecular subtypes. Interleukin17 and Ki67 expressions were assessed using immunohistochemistry examination and data were analysed using the Pearson andSpearman test to assess correlations between the two variables.ResultsGeneral characteristics of the sample in this study were breast cancer patients aged >40 years (73.7%), histopathological subtypesof non-specific invasive carcinoma (84.2%), high tumor rates (78.9%), non-dominant TILs (94.7%) and molecular subtype luminal B(55.3%). There is no relationship between IL-17 expression and Ki67 proliferation index (p 0.72 and OR of 1.417), even though lowerexpression of IL-17 showed a higher Ki67 proliferation index.ConclusionExpression of IL-17 cannot describe the Ki67 proliferation index in breast carcinoma. Studies using another analytical techniques andlarge sample size are suggested to obtain more accurate results.]]>
